Age
|
Range (years)
|
18–64
|
18–61
|
23–47
|
18–56
|
19–67
|
19–67
|
Mean ± SD (median)
|
35.5 ± 12.7 (32)
|
30.0 ± 11.9 (26)
|
32.8 ± 6.7 (31)
|
28.5 ± 9.5 (27)
|
36.8 ± 15.9 (36)
|
40.0 ± 13.6 (40.5)
|
Gender, n (%) female
|
46 (82.1)
|
22 (88)
|
21 (87.5)
|
28 (84.8)
|
15 (93.8)
|
28 (93.3)
|
Ethnicity, n (%)
|
Caucasian
|
29 (48.3)
|
9 (36)
|
14 (58.3)
|
14 (42.4)
|
6 (37.5)
|
20 (66.7)
|
African Canadian
|
14 (23.3)
|
7 (28)
|
1 (4.2)
|
8 (24.2)
|
2 (12.5)
|
4 (13.3)
|
Asian
|
9 (15)
|
5 (20)
|
3 (12.5)
|
5 (11.6)
|
2 (12.5)
|
2 (6.7)
|
Othera
|
8 (13.3)
|
4 (16)
|
6 (25)
|
6 (18.2)
|
6 (37.5)
|
4 (13.3)
|
Clinical featuresb, n (%)
|
Rash
|
8 (14.3)
|
12 (48)
|
N/A
|
11 (33.3)
|
3 (18.8)
|
0
|
Mucocutaneous
|
9 (16.1)
|
9 (36)
|
N/A
|
0
|
2 (12.5)
|
0
|
Alopecia
|
4 (7.1)
|
7 (28)
|
N/A
|
4 (12.1)
|
5 (31.2)
|
1 (3.3)
|
Arthritis
|
13 (23.2)
|
13 (52)
|
N/A
|
3 (9.1)
|
9 (56.2)
|
0
|
Serositis
|
8 (14.3)
|
4 (16)
|
N/A
|
2 (6.1)
|
1 (6.2)
|
0
|
Myositis
|
1 (1.8)
|
0
|
N/A
|
0
|
1 (6.2)
|
0
|
Hematological
|
6 (10.7)
|
6 (24)
|
N/A
|
2 (6.1)
|
3 (18.8)
|
0
|
Fever
|
3 (5.4)
|
1 (4)
|
N/A
|
1 (3.0)
|
2 (12.5)
|
0
|
Nephritis (≥1 or more SLEDAI-2 K criteria)
|
59 (98.3)c
|
0
|
N/A
|
33 (100)
|
0
|
1 (3.3)
|
Vasculitis
|
3 (5.4)
|
7 (28)
|
N/A
|
2 (6.1)
|
3 (18.8)
|
0
|
SLEDAI-2 K, mean ± SD (median)
|
15.6 ± 7.4 (16)
|
10.1 ± 4.7 (10)
|
N/A
|
14.2 ± 5.6 (14)
|
7.2 ± 2.7 (8)
|
1.7 ± 1.9 (1)
|
Creatinine, mean ± SD (median)
|
118.0 ± 78.8 (87)
|
64.5 ± 9.6 (62)
|
N/A
|
91.8 ± 81.1 (69)
|
69.2 ± 16.0 (70.5)
|
81.8 ± 25.3 (75.5)
|
Medicationsb
|
Prednisone (mg/day), mean ± SD (median)
|
28.5 ± 20.8 (30)
|
10.8 ± 30.4 (0)
|
N/A
|
21.8 ± 18.8 (15)
|
8.5 ± 13.2 (4)
|
6.1 ± 6.9 (4)
|
Anti-malarials, n (%)
|
31 (55.4)
|
15 (60)
|
N/A
|
21 (63.6)
|
13 (81.2)
|
24 (80)
|
Immunosuppressives, n (%)
|
55 (91.7)
|
5 (20)
|
N/A
|
27 (81.8)
|
10 (62.5)
|
22 (73.3)
|
Azathioprine, n (%)
|
9 (16.1)
|
3 (12)
|
N/A
|
11 (33.3)
|
3 (18.8)
|
9 (30)
|
Mycophenolate mofetil, n (%)
|
15 (26.8)
|
1 (4)
|
N/A
|
9 (27.3)
|
2 (12.5)
|
10 (33.3)
|
Methotrexate, n (%)
|
1 (1.8)
|
1 (4)
|
N/A
|
1 (3.0)
|
5 (31.2)
|
1 (3.3)
|